ICU Medical (NASDAQ:ICUI) Announces Earnings Results, Beats Estimates By $0.46 EPS

ICU Medical (NASDAQ:ICUI) released its quarterly earnings results on Thursday. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.46, FiscalAI reports. The company had revenue of $547.88 million during the quarter, compared to analysts’ expectations of $533.44 million. ICU Medical had a net margin of 1.39% and a return on equity of 7.94%. The business’s quarterly revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the company earned $2.10 earnings per share. ICU Medical updated its FY 2026 guidance to 8.600-9.000 EPS.

Here are the key takeaways from ICU Medical’s conference call:

• Second-quarter results exceeded expectations on earnings momentum, with organic revenue growth of 6%, adjusted EBITDA up 10% to $110 million, and adjusted EPS up 13% to $2.37.
• ICU Medical raised and narrowed its 2026 adjusted EBITDA guidance to $415 million–$435 million and adjusted EPS guidance to $8.60–$9.00, while increasing expected full-year adjusted gross margin to approximately 41.5%.
• Infusion Systems and Consumables delivered record sales, growing 12% and 5% organically, respectively. Management expects Systems organic growth at or above 6% in the near term and continued mid-single-digit growth in Consumables.
• Strong free cash flow of $62 million, including a $20 million tariff refund, enabled $50 million of debt repayment and reduced net leverage to 2.3 times; management remains on track for approximately 2 times leverage by year-end.
• The outlook still faces pressure from tariffs, unfavorable currencies, and higher oil and diesel costs, while Vital Care declined 4% organically and is expected to remain slightly down for the full year. Some pump installations occurred earlier than expected, and the timing of Medfusion 5000 FDA resubmission and CAD development remains uncertain.

ICU Medical Stock Performance

Shares of NASDAQ ICUI traded up $18.19 during mid-day trading on Friday, hitting $184.56. The company had a trading volume of 931,233 shares, compared to its average volume of 304,941. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.34 and a quick ratio of 1.17. The business’s 50-day simple moving average is $151.64 and its 200-day simple moving average is $141.02. ICU Medical has a 12 month low of $107.00 and a 12 month high of $192.85. The firm has a market cap of $4.61 billion, a P/E ratio of 156.41, a PEG ratio of 2.58 and a beta of 0.74.

Insider Activity

In other ICU Medical news, Director David C. Greenberg sold 2,424 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the sale, the director owned 7,960 shares in the company, valued at approximately $978,363.60. This trade represents a 23.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total value of $303,623.76. Following the completion of the sale, the vice president owned 19,460 shares of the company’s stock, valued at $2,414,596.80. This represents a 11.17% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Janus Henderson Group PLC lifted its position in ICU Medical by 4.2% in the fourth quarter. Janus Henderson Group PLC now owns 2,576,756 shares of the medical instruments supplier’s stock worth $367,625,000 after purchasing an additional 103,220 shares during the period. Millennium Management LLC raised its stake in shares of ICU Medical by 173.4% in the 3rd quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock valued at $130,638,000 after buying an additional 690,694 shares in the last quarter. State Street Corp raised its stake in shares of ICU Medical by 2.8% in the 4th quarter. State Street Corp now owns 942,670 shares of the medical instruments supplier’s stock valued at $134,491,000 after buying an additional 25,545 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of ICU Medical by 5.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 920,776 shares of the medical instruments supplier’s stock worth $131,370,000 after acquiring an additional 47,783 shares during the period. Finally, Ameriprise Financial Inc. lifted its holdings in shares of ICU Medical by 34.0% during the 3rd quarter. Ameriprise Financial Inc. now owns 803,542 shares of the medical instruments supplier’s stock worth $96,393,000 after acquiring an additional 203,746 shares during the period. 96.10% of the stock is currently owned by institutional investors and hedge funds.

More ICU Medical News

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Quarterly earnings beat expectations: ICU Medical reported second-quarter adjusted EPS of $2.37, up from $2.10 a year earlier and well above the $1.91 analyst consensus. Revenue reached $547.9 million versus expectations of $533.4 million, with infusion systems cited as a key growth driver. ICU Medical Q2 results beat analyst expectations, driven by infusion systems
• Positive Sentiment: Higher 2026 earnings outlook: The company raised or updated fiscal 2026 EPS guidance to $8.60–$9.00, above the approximately $7.83 consensus estimate. This indicates management expects stronger profitability than Wall Street previously modeled. ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance
• Positive Sentiment: Analysts raised price targets: Piper Sandler increased its target from $163 to $195 and maintained an “overweight” rating. Needham raised its target from $165 to $187 and reiterated a “buy” rating. The revisions reinforce the view that the earnings beat and guidance update improve ICU Medical’s growth outlook. ICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings
• Neutral Sentiment: Valuation remains demanding: Despite the favorable earnings news, ICU Medical trades at a high earnings multiple, meaning further gains may depend on the company delivering against its elevated guidance and sustaining growth.

Analyst Upgrades and Downgrades

ICUI has been the subject of several research analyst reports. Needham & Company LLC boosted their price objective on ICU Medical from $165.00 to $187.00 and gave the stock a “buy” rating in a research report on Friday. Sanford C. Bernstein downgraded ICU Medical to a “market perform” rating in a research report on Monday, June 15th. Wall Street Zen raised ICU Medical from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Zacks Research lowered ICU Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Finally, Piper Sandler increased their price objective on ICU Medical from $163.00 to $195.00 and gave the company an “overweight” rating in a research report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $192.80.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.